✨ Free AI Report
Nymox Pharmaceutical Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nymox Pharmaceutical Corporation
Company Research

Nymox Pharmaceutical Corporation: Business Overview, Financials & Competitive Analysis

Nymox Pharmaceutical Corporation is a biopharmaceutical company engaged in therapeutics in development for enlarged prostate (BPH). The company specializes in research and development of therapeutics and diagnostics w...

Analyst-debate audio for Nymox Pharmaceutical Corporation

AskCyborg analysts argue the bull and bear cases for Nymox Pharmaceutical Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

Early-stage biotech dependent on achieving regulatory approval for lead BPH candidate to validate decades of development...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Nymox Pharmaceutical Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Nymox Pharmaceutical Corporation Overview

Pro stress-test →

Nymox Pharmaceutical Corporation is a biopharmaceutical company engaged in therapeutics in development for enlarged prostate (BPH). The company specializes in research and development of therapeutics and diagnostics with emphasis on products for the unmet needs of the rapidly aging male population in developed economies.

Strategic Profile

Pro stress-test →

The lead drug candidate Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients. The company will soon file for approval in major economies including the United States and Europe, while also developing Fexapotide for early-stage, non-aggressive prostate cancer.

Competitive Landscape

Pro stress-test →

Nymox competes in the enlarged prostate (BPH) therapeutic market. Major pharma competitors (GlaxoSmithKline Avodart, Merck Proscar) and other biotech firms developing BPH treatments compete in this space. Nymox's differentiation rests on single-injection delivery mechanism, but regulatory pathway and market access remain uncertain.

Industry Context

Nymox Pharmaceutical Corporation operates in Biopharmaceutical / Clinical-stage Drug Development.

Key facts

Founded: 1989 · Headquarters: Nassau, Bahamas · Market cap: $8.51M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Nymox Pharmaceutical Corporation.

  • Lead drug Fexapotide Triflutate (NX-1207) completed Phase III clinical trials for BPH and Phase II trials for low-grade localized prostate cancer
  • December 2024 move to OTCQB listing from prior status, making stock eligible for proprietary broker-dealer quotations
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2024Stock resumed trading on OTCQB Venture Market under symbol NYMXF
  • August 2024Filed Annual Report with SEC
  • +1 moreTrack every material event for Nymox Pharmaceutical Corporation as it happens. Explore monitoring →
Get alerted when Nymox Pharmaceutical Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Avodart (Dutasteride)5-alpha reductase inhibitor for BPH→Proscar (Finasteride)5-alpha reductase inhibitor for BPH→Flomax (Tamsulosin)Alpha blocker for BPH→

Compare Nymox Pharmaceutical Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nymox Pharmaceutical Corporation operates in Biopharmaceutical / Clinical-stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-stage Drug Development research →
NEW · MCP server

Ask your AI assistant about Nymox Pharmaceutical Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nymox Pharmaceutical Corporation and its top competitor on Cyborg Score”
“What did Nymox Pharmaceutical Corporation do this quarter?”
“Is Nymox Pharmaceutical Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Nymox Pharmaceutical Corporation do?+
Nymox Pharmaceutical Corporation is a biopharmaceutical company engaged in therapeutics in development for enlarged prostate (BPH). The company specializes in research and development of therapeutics and diagnostics w...
What is Nymox Pharmaceutical Corporation's Cyborg Score?+
Nymox Pharmaceutical Corporation has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nymox Pharmaceutical Corporation's main competitors?+
Named competitors include Avodart (Dutasteride), Proscar (Finasteride), Flomax (Tamsulosin). The full competitive landscape is in the AskCyborg report.
How can I get the full Nymox Pharmaceutical Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nymox Pharmaceutical Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nymox Pharmaceutical Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score